Trial Profile
Phase 1 Study of Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Vididencel (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Mendus
- 03 Nov 2023 According to a Mendus Media Release,the data from this Phase 1 clinical trial on its lead development program vididencel, were published in the peer-reviewed medical journal HemaSphere.
- 03 Nov 2023 Results published in a Mendus Media Release.
- 03 Nov 2023 According to a Mendus Media Release, Prof. Dr. Arjan van de Loosdrech is the Principal Investigator of this trial.